


(Figure 1) has extremely limited stability in solution and has been shown to undergo spontaneous Masamune–Bergman rearrangement without any external activator.<sup>[6]</sup> Through this rearrangement, **1** generates *p*-benzyne biradical **2**, which



**Figure 1.** Structure of the C-1027 chromophore **1** and its Masamune–Bergman rearrangement to **3**.

## Natural Products Synthesis

### Synthesis of the C-1027 Chromophore Framework through Atropselective Macrolactonization\*\*

Masayuki Inoue,\* Takeo Sasaki, Suguru Hatano, and Masahiro Hirama\*

C-1027 is a chromoprotein enediyne natural product with potent in vitro and in vivo cytotoxicity against a variety of cancer cell lines.<sup>[1]</sup> It is a member of the subset of enediyne antibiotics that includes neocarzinostatin,<sup>[2]</sup> kedarcidin,<sup>[3]</sup> and maduropeptin.<sup>[4,5]</sup> Each of these agents is composed of protein and small-molecule (chromophore) components, which form a 1:1 complex. The C-1027 chromophore **1**

exerts its potent toxicity by abstracting hydrogen atoms (**2** → **3**) from the backbone of DNA to cleave the double strand.<sup>[7]</sup> This chemical instability and its complex structure distinguish **1** as a challenging target for total synthesis.<sup>[8–11]</sup>

The structure of **1** is highly unusual, characterized by a chlorocatechol-containing ansa-bridge, a strained bicyclo[7.3.0]dodecatrienediyne, an appended benzoxazine,<sup>[12]</sup> and an aminosugar.<sup>[13]</sup> The synthetic challenge presented by **1** is heightened by the presence of nonbiaryl atropisomerism arising from hindered rotation of the chlorocatechol ring in the ansa-bridge.<sup>[14,15]</sup> Herein we present the synthesis of the C-1027 chromophore framework through a newly designed atropselective macrocyclization.

Our synthetic strategy is outlined in Scheme 1. The total synthesis of **1** would be attained from its framework **4** by attaching the amino sugar<sup>[16]</sup> and the benzoxazine, followed by introducing two olefins (C4–C5 and C11–C12).<sup>[17]</sup> As the nine-membered diyne of **4** could be chemically unstable, as suggested by experiments on a model compound,<sup>[18]</sup> the macrolactone system would have to be constructed prior to the nine-membered ring.<sup>[19]</sup> We planned to form this strained nine-membered diyne **4** by LiN(TMS)<sub>2</sub>/CeCl<sub>3</sub>-promoted cyclization of **5**.<sup>[16,17,19b,20]</sup> The highly unsaturated macrocycle **5** was to be synthesized through the coupling of the three fragments **6**, **7**, and **8** in a convergent manner.


The synthesis of the five-membered ring **14** bearing the β-tyrosine moiety was improved from a previously published procedure,<sup>[21]</sup> and started with the known intermediate **9** (Scheme 2).<sup>[22]</sup> Nucleophilic addition of vinylmagnesium bromide to enone **9** occurred from the opposite side of the bulky TBS ether to afford tertiary alcohol **10** as the sole isomer.

[\*] Prof. Dr. M. Inoue, Dr. T. Sasaki, S. Hatano, Prof. Dr. M. Hirama  
Department of Chemistry  
Graduate School of Science, Tohoku University  
Sendai 980-8578 (Japan)  
Fax: (+81) 22-217-6566  
E-mail: inoue@ykbsc.chem.tohoku.ac.jp  
hirama@ykbsc.chem.tohoku.ac.jp


Prof. Dr. M. Inoue  
Research and Analytical Center for Giant Molecules  
Graduate School of Science, Tohoku University  
Sendai 980-8578 (Japan)

[\*\*] This work was supported by CREST, Japan Science and Technology Agency (JST). A fellowship to T.S. from the Japanese Society for the Promotion of Science (JSPS) is gratefully acknowledged.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.



**Scheme 1.** Retrosynthesis of the C-1027 chromophore. MOM = methoxymethyl, MPM = *p*-methoxyphenylmethyl, TES = triethylsilyl, Boc = *tert*-butoxycarbonyl.



**Scheme 2.** Reagents and conditions: a)  $\text{CH}_2=\text{CHMgBr}$ ,  $\text{Et}_2\text{O}$ ,  $-70 \rightarrow 0^\circ\text{C}$ , 83%; b)  $\text{O}_3$ ,  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{pyridine}$  (4:4:1),  $-80^\circ\text{C}$ ; then  $\text{Me}_2\text{S}$ ,  $-60^\circ\text{C} \rightarrow \text{RT}$ ; c)  $\text{HC}\equiv\text{CMgBr}$ , toluene,  $-85^\circ\text{C} \rightarrow \text{RT}$ , 62% (over two steps); d)  $\text{MsCl}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-70^\circ\text{C}$ ; then  $\text{DBU}$ ,  $-70^\circ\text{C} \rightarrow \text{RT}$ , 69%; e)  $\text{TBAF}$ ,  $\text{THF}$ ,  $0^\circ\text{C}$ , 95%; f)  $\text{MOMCl}$ ,  $i\text{Pr}_2\text{NEt}$ ,  $(\text{CH}_2\text{Cl})_2$ ,  $40^\circ\text{C}$ , 86%; g) **7** (1.1 equiv),  $\text{CsF}$ ,  $\text{DMF}$ ,  $75^\circ\text{C}$ , 77%. TBS = *tert*-butyldimethylsilyl; Ms = methanesulfonyl; DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene; TBAF = tetrabutylammonium fluoride; MOM = methoxymethyl; DMF = *N,N*-dimethylformamide.

Selective ozonolysis of the terminal olefin of **10** and subsequent reductive workup generated aldehyde **11**. Treatment of **11** with ethynylmagnesium bromide in toluene exclusively produced diol **12** bearing the  $\beta$ -hydroxy group at C8. The stereochemical outcome of the reaction was presumably governed by magnesium chelation and the presence of the bulky iodine, forcing the nucleophile to attack from the


less hindered side of the five-membered chelate **15**. The secondary alcohol of **12** was selectively mesylated with  $\text{MsCl}$  and  $\text{Et}_3\text{N}$ , and the monomesylate was converted into epoxide **13** by the addition of  $\text{DBU}$  (one-pot reaction). Next, the TBS group of **13** was replaced by a MOM group to give **6** in a two-step sequence. Finally, the  $\beta$ -tyrosine moiety **7**<sup>[21]</sup> was coupled to **6** by the action of  $\text{CsF}$  in  $\text{DMF}$ ,<sup>[23]</sup> leading to adduct **14**.

To evaluate potential strategies for the desired atropselective macrolactonization, substrate **19** was first synthesized (Scheme 3). The tertiary alcohol of **14** was converted into the TMS ether, and the TMS group was also introduced to the terminal acetylene to afford **16**. Sonogashira coupling<sup>[24]</sup> of **16** with acetylene moiety **8**<sup>[19a]</sup> in the presence of catalytic  $[\text{Pd}(\text{PPh})_4]$  and  $\text{CuI}$  led to **17**. Treatment of **17** with  $\text{K}_2\text{CO}_3$  in methanol resulted in simultaneous removal of the acetyl and two TMS groups to produce **18**, and subsequent saponification of the methyl ester of **18** with  $\text{KOH}$  gave rise to seco-acid **19**.


Macrolactonization of **19** was successfully realized by two methods, but with a non-atropselective outcome. Carboxylic acid **19** was treated with 2,2'-dipyridyl disulfide and  $\text{PPh}_3$  to give the corresponding thioester, which was heated at reflux in toluene,<sup>[25]</sup> resulting in the formation of macrolactone **20** and **21** in 50% yield (1:1).<sup>[19a]</sup> A higher yield of **20** was achieved by the powerful method recently developed by Shiina and co-workers.<sup>[26]</sup> Treatment of **19** with  $\text{MNBA}$  and  $\text{DMAP}$  at  $40^\circ\text{C}$  produced macrolactones **20** and **21** (1:1.1 ratio in 65% combined yield). Importantly, the ratio of the atropisomers was unaffected under the two different conditions, and thus the structure of the substrate was likely to be the decisive factor in the selectivity of the reaction. Furthermore, isomerization to enrich the desired atropisomer **20** was unsuccessful. Separate heating of atropisomers **20** and **21** at  $160^\circ\text{C}$  in deuterated 1,2-dichlorobenzene for 12 h did not result in isomerization, which suggests that these macrocycles are highly rigid.<sup>[27,28]</sup> Consequently, selective formation of the desired atropisomer would be possible only by controlling the transition state of the macrolactonization by using an appropriately functionalized substrate.

To examine the effect of substituents of the aromatic ring on selectivity, the OMOM group at C23 of **19** was replaced with  $\text{OH}$  in the alternative substrate **27** (Scheme 3). First, bis-MOM ether **14** was successfully transformed into mono-MOM ether **22** by treatment with  $\text{TFA}$  and subsequent reattachment of Boc to the C18 amine. After conversion of phenol **22** into pivalate ester **23**, TMS groups were introduced at 9-OH and at the C6-methyne to produce Sonogashira coupling substrate **24**. Adduct **25** was then obtained by coupling **24** with **8** in the presence of catalytic  $\text{Pd}^0$  and  $\text{CuI}$ . Deprotection of four protecting groups (two TMS, Ac, and Piv) from **25** with  $\text{K}_2\text{CO}_3$  in methanol and subsequent treatment with  $\text{KOH}$  resulted in seco-acid **27** with the free 23-OH group. Surprisingly, macrolactonization of **27** by using the Corey–Nicolaou thioester method generated solely the undesired atropisomer **28** in modest yield.

From NOESY data and molecular modeling (Macro-Model Ver 8.0),<sup>[29]</sup> all the macrolactones (**20**, **21**, and **28**) were found to have similar conformations. The structure of **28** is shown as a representative example (Figure 2), in which it can




be seen that the terminal acetylene and the chlorocatechol are perpendicular to the macrocycle plane. It is evident that the



**Figure 2.** Three-dimensional structure of **28** based on NOESY data (C<sub>6</sub>D<sub>6</sub>) and molecular modeling.

1,5 hydroxy groups (9-OH and 23-OH) are in spatial proximity, suggesting hydrogen bonding. This hydrogen bonding could also fix the conformation of the transition state (Figure 3), which explains the sole formation of **28** from **27**. In the cyclization of **19**, the larger unfavorable steric



**Figure 3.** Potential hydrogen bonding in the transition state of the macrolactonization reaction.

interaction between the 23-OMOM group and the tertiary 9-OH group could counteract the attractive hydrogen bond, which could be the reason for the nonstereoselective outcome observed. Hence, the atropselectivity of the macrolactonization appears to be controlled by the balance between steric interaction and hydrogen bonding of the substituents at C9 and C23.

From these considerations, placement of a bulky protecting group on the tertiary 9-OH group could force an atropselective macrolactonization to the desired isomer, because both increased steric interaction with the 23-OMOM group and elimination of the hydrogen bond would impose an energetic penalty on the transition state of the unwanted atropisomer. For undertaking an experimental verification of this hypothesis, we designed a new macrolactonization substrate **31**, which bears 23-OMOM and 9-OTES groups (Scheme 4).


As shown in Scheme 4, seco-acid **31** was synthesized from **14** in a route similar to that used for **19**. The TES group was introduced at the tertiary alcohol function of **14**, and the acetylene moiety was transformed to its TMS-protected form **29**. Condensation of **8** and **29** under Sonogashira conditions led to diyne **30**, whose acetate, methyl esters, and TMS group were hydrolyzed with KOH in THF/MeOH/H<sub>2</sub>O, without affecting the TES ether, giving **31**.

Atropselective macrolactonization of seco-acid **31** was effected by using the MNBA method. Upon treatment of **31** with MNBA and DMAP in refluxing CH<sub>2</sub>Cl<sub>2</sub>, the desired isomer **32** was formed with 4:1 atropselectivity and isolated in

61% yield.<sup>[31]</sup> Remarkably, the yield of the desired atropisomer (**32** versus **20**) was doubled by strategic protection of the 9-OH group.

With the desired ansa macrolide **32** in hand, our next focus was to construct the nine-membered diyne ring. Before doing so, the reaction conditions of protecting- and functional-group manipulations were carefully tuned. First, the cyclopentylidene ketal of **32** was selectively removed with TFOH in CF<sub>3</sub>CH<sub>2</sub>OH/THF<sup>[30]</sup> without affecting other acid-labile protecting groups (MOM, TES, MPM, and Boc) to afford 1,2-diol **34**. After conversion of **34** into tris-TES ether **35**, another Boc group was introduced by using (Boc)<sub>2</sub>O and DMAP to mask the acidic 18-NH proton of **35**, leading to biscarbamate **36**.<sup>[32]</sup> The primary alcohol at C5 was selectively deprotected by using HF·py to produce **37**, which was oxidized to aldehyde **5** with (COCl)<sub>2</sub> and DMSO.

Cyclization of **5** was promoted by a 1:1 mixture of LiN(TMS)<sub>2</sub> and CeCl<sub>3</sub> in THF from −50°C to room temperature, giving rise to the strained nine-membered diyne **4** as the sole isomer in 30% yield. Thus, this LiN(TMS)<sub>2</sub>/CeCl<sub>3</sub> reagent combination proved to be applicable to the highly complex and conformationally rigid system **5**. The stereochemical structure of **4**, including the newly formed β secondary alcohol, was unambiguously determined by ROESY experiments in [D<sub>6</sub>]DMSO. The correct atropisomerism of **4** was again confirmed at this stage, indicating the high energy barrier to rotation of the chlorocatechol in all the synthetic intermediates. Diyne **4** slowly decomposed at room temperature, presumably through Cope rearrangement, as



**Scheme 4.** Reagents and conditions: a) TESCl, imidazole, DMF, room temperature, 98%; b) TMSCl, LiN(TMS)<sub>2</sub>, THF, −78°C, 87%; c) **8** (1.2 equiv), [Pd(PPh<sub>3</sub>)<sub>4</sub>] (20 mol%), CuI (40 mol%), iPr<sub>2</sub>NEt, DMF, room temperature, 80%; d) KOH, THF/H<sub>2</sub>O/MeOH (5:1:1), 90%; e) MNBA (2.4 equiv), DMAP (4.8 equiv), CH<sub>2</sub>Cl<sub>2</sub> (1 mm), 40°C, slow addition of **31** over 12 h, 61% (**32**), 15% (**33**), 5% (dimer); f) TFOH, CF<sub>3</sub>CH<sub>2</sub>OH/THF (5:1), 65%; g) TESCl, imidazole, DMF, 40°C, 93%; h) (Boc)<sub>2</sub>O, DMAP, MeCN, 40°C, 100%; i) HF·py, THF, 0°C, 78%; j) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, −78°C, 100%; k) LiN(TMS)<sub>2</sub> (58 equiv), CeCl<sub>3</sub> (61 equiv), THF (1 mm), −50→0°C, 30%. Tf = trifluoromethanesulfonyl, DMSO = dimethyl sulfoxide.

demonstrated with previously synthesized model compounds.<sup>[33]</sup>

In conclusion, we achieved the stereoselective synthesis of the C-1027 chromophore framework through atropselective macrolactonization. The key features in this synthesis were 1) strategic protection of a 1,5-diol to attain atropselective macrocyclization, and 2) LiN(TMS)<sub>2</sub>/CeCl<sub>3</sub>-promoted acetylide-aldehyde condensation to build the nine-membered diyne ring in a highly unsaturated and heavily substituted macrocycle. Further studies on the total synthesis of the C-1027 chromophore from **4** are currently underway in this laboratory.

Received: July 26, 2004

**Keywords:** alkynes · antitumor agents · atropisomerism · lactones · macrocycles

- [1] a) T. Otani, Y. Minami, T. Marunaka, R. Zhang, M.-Y. Xie, *J. Antibiot.* **1988**, *41*, 1580–1585; b) Y. Zhen, S. Ming, Y. Bin, T. Otani, H. Saito, Y. Yamada, *J. Antibiot.* **1989**, *42*, 1294–1298.
- [2] *Neocarzinostatin* (Eds.: H. Maeda, K. Edo, N. Ishida), Springer, Tokyo, **1997**.
- [3] a) J. E. Leet, D. R. Schroeder, S. J. Hofstead, J. Golik, K. L. Colson, S. Huang, S. E. Kloor, T. W. Doyle, J. A. Matson, *J. Am. Chem. Soc.* **1992**, *114*, 7946–7948; b) S. Kawata, S. Ashizawa, M. Hiram, *J. Am. Chem. Soc.* **1997**, *119*, 12012–12013.
- [4] D. R. Schroeder, K. L. Colson, S. E. Kloor, N. Zein, D. R. Langley, M. S. Lee, J. A. Matson, T. W. Doyle, *J. Am. Chem. Soc.* **1994**, *116*, 9351–9352.
- [5] For a review on chromoprotein antibiotics and other enediyne natural products, see: Z. Xi, I. H. Goldberg in *Comprehensive Natural Products Chemistry*, Vol. 7 (Eds.: D. H. R. Barton, K. Nakanishi), Elsevier, Dordrecht, **1999**, pp. 553–592.
- [6] a) Y. Minami, K. Yoshida, R. Azuma, M. Saeki, T. Otani, *Tetrahedron Lett.* **1993**, *34*, 2633–2636; b) K. Yoshida, Y. Minami, R. Azuma, M. Saeki, T. Otani, *Tetrahedron Lett.* **1993**, *34*, 2637–2640; c) K. Yoshida, Y. Minami, T. Otani, Y. Tada, M. Hiram, *Tetrahedron Lett.* **1994**, *35*, 5253–5256; d) K. Iida, S. Fukuda, T. Tanaka, M. Hiram, S. Imajo, M. Ishiguro, K. Yoshida, T. Otani, *Tetrahedron Lett.* **1996**, *37*, 4997–5000.
- [7] a) Y. Sugiura, T. Matsumoto, *Biochemistry* **1993**, *32*, 5548–5553; b) Y. Xu, X. Zhen, Y. Zhen, I. H. Goldberg, *Biochemistry* **1995**, *34*, 12451–12460.
- [8] Total syntheses of the nine-membered ring enediynes were reported: N-1999A2: a) S. Kobayashi, S. Ashizawa, Y. Takahashi, Y. Sugiura, M. Nagaoka, M. J. Lear, M. Hiram, *J. Am. Chem. Soc.* **2001**, *123*, 11294–11295; neocarzinostatin chromophore: b) A. G. Myers, J. Liang, M. Hammond, P. M. Harrington, Y. Wu, E. Y. Kuo, *J. Am. Chem. Soc.* **1998**, *120*, 5319–5320; c) A. G. Myers, R. Glatthar, M. Hammond, P. M. Harrington, E. Y. Kuo, J. Liang, S. E. Schaus, Y. Wu, J.-N. Xiang, *J. Am. Chem. Soc.* **2002**, *124*, 5380–5401.
- [9] For recent synthetic studies of the enediyne natural products from this laboratory, see: neocarzinostatin chromophore: a) K. Toyama, S. Iguchi, H. Sakazaki, T. Oishi, M. Hiram, *Bull. Chem. Soc. Jpn.* **2001**, *74*, 997–1008; kedarcidin: b) F. Yoshimura, S. Kawata, M. Hiram, *Tetrahedron Lett.* **1999**, *40*, 8281–8285; c) I. Ohashi, M. J. Lear, F. Yoshimura, M. Hiram, *Org. Lett.* **2004**, *6*, 719–722; maduropeptin: d) N. Kato, S. Shimamura, Y. Kikai, M. Hiram, *Synlett* **2004**, 2107–2110, and references therein.
- [10] For the synthesis of the protected kedarcidin chromophore aglycon, see: A. G. Myers, P. C. Hogan, A. R. Hurd, S. D. Goldberg, *Angew. Chem.* **2002**, *114*, 1104–1109; *Angew. Chem. Int. Ed.* **2002**, *41*, 1062–1066.
- [11] For reviews on the syntheses of enediyne compounds, see: a) K. C. Nicolaou, W.-M. Dai, *Angew. Chem.* **1991**, *103*, 1453–1481; *Angew. Chem. Int. Ed. Engl.* **1991**, *30*, 1387–1416; b) S. J. Danishefsky, M. D. Shair, *J. Org. Chem.* **1996**, *61*, 16–44.
- [12] M. Shibuya, H. Sakurai, T. Maeda, E. Nishiwaki, M. Saito, *Tetrahedron Lett.* **1986**, *27*, 1351–1354.
- [13] a) K. Iida, T. Ishii, M. Hiram, T. Otani, Y. Minami, K. Yoshida, *Tetrahedron Lett.* **1993**, *34*, 4079–4082; b) M. F. Semmelhack, Y. Jiang, D. Ho, *Org. Lett.* **2001**, *3*, 2403–2406.
- [14] For a review, see: P. Lloyd-Williams, E. Giralt, *Chem. Soc. Rev.* **2001**, *30*, 145–157.
- [15] Only a few examples have been reported on the stereoselective synthesis of nonbiaryl stereogenic axes in natural product syntheses; see: a) D. A. Evans, M. R. Wood, B. W. Trotter, T. I. Richardson, J. C. Barrow, J. L. Katz, *Angew. Chem.* **1998**, *110*, 2864–2868; *Angew. Chem. Int. Ed.* **1998**, *37*, 2700–2703; b) D. A. Evans, C. J. Dinsmore, P. S. Watson, M. R. Wood, T. I. Richardson, B. W. Trotter, J. L. Katz, *Angew. Chem.* **1998**, *110*, 2868–2872; *Angew. Chem. Int. Ed.* **1998**, *37*, 2704–2708; c) M. E. Layton, C. A. Morales, M. D. Shair, *J. Am. Chem. Soc.* **2002**, *124*, 773–775; d) K. C. Nicolaou, C. N. C. Boddy, *J. Am. Chem. Soc.* **2002**, *124*, 10451–10455; see also references [9b] and [10].
- [16] I. Sato, Y. Akahori, T. Sasaki, T. Kikuchi, M. Hiram, *Chem. Lett.* **1999**, 867–868.
- [17] M. Inoue, S. Hatano, M. Kodama, T. Sasaki, T. Kikuchi, M. Hiram, *Org. Lett.* **2004**, *6*, 3833–3836.
- [18] K. Iida, M. Hiram, *J. Am. Chem. Soc.* **1994**, *116*, 10310–10311.
- [19] a) T. Sasaki, M. Inoue, M. Hiram, *Tetrahedron Lett.* **2001**, *42*, 5299–5303; b) M. Inoue, T. Kikuchi, M. Hiram, *Tetrahedron Lett.* **2004**, *45*, 6439–6442.
- [20] For other studies on bicyclo[7.3.0]dodecadiyne formation, see: a) P. A. Wender, M. Harmata, D. Jeffery, C. Mukai, J. Suffert, *Tetrahedron Lett.* **1988**, *29*, 909–912; b) P. A. Wender, J. A. McKinney, C. Mukai, *J. Am. Chem. Soc.* **1990**, *112*, 5369–5370; c) T. Doi, T. Takahashi, *J. Org. Chem.* **1991**, *56*, 3465–3467; d) P. Magnus, R. Carter, M. Davies, J. Elliott, T. Pittner, *Tetrahedron* **1996**, *52*, 6283–6306; e) H. Tanaka, H. Yamada, A. Matsuda, T. Takahashi, *Synlett* **1997**, 381–383; f) S. Caddick, V. M. Delisser, V. E. Doyle, S. Khan, A. G. Avent, S. Vile, *Tetrahedron* **1999**, *55*, 2737–2754, and references therein.
- [21] I. Sato, T. Kikuchi, M. Hiram, *Chem. Lett.* **1999**, 511–512.
- [22] a) M. Hiram, T. Gomibuchi, K. Fujiwara, Y. Sugiura, M. Uesugi, *J. Am. Chem. Soc.* **1991**, *113*, 9851–9853; b) C. R. Johnson, M. P. Braun, *J. Am. Chem. Soc.* **1993**, *115*, 11014–11015.
- [23] S. Kawata, M. Hiram, *Tetrahedron Lett.* **1998**, *39*, 8707–8710.
- [24] K. Sonogashira in *Comprehensive Organic Synthesis*, Vol. 3 (Eds.: B. M. Trost, I. Fleming), Pergamon, London, **1990**, pp. 521–549.
- [25] E. J. Corey, K. C. Nicolaou, *J. Am. Chem. Soc.* **1974**, *96*, 5614–5616.
- [26] a) I. Shiina, M. Kubota, R. Ibuka, *Tetrahedron Lett.* **2002**, *43*, 7535–7539; b) I. Shiina, M. Kubota, H. Oshiumi, M. Hashizume, *J. Org. Chem.* **2004**, *69*, 1822–1830.
- [27] For an excellent example of the selective isomerization of atropisomers in the context of a total synthesis of vancomycin, see: D. L. Boger, S. Miyazaki, S. H. Kim, J. H. Wu, S. L. Castle, O. Loiseleur, Q. Jin, *J. Am. Chem. Soc.* **1999**, *121*, 10004–10011.
- [28] Interestingly, the facile atropisomerism of kedarcidin synthetic intermediates has been observed: A. G. Myers, A. R. Hurd, P. C. Hogan, *J. Am. Chem. Soc.* **2002**, *124*, 4583–4585. see also reference [10].

- [29] F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, W. C. Still, *J. Comput. Chem.* **1990**, *11*, 440–467.
- [30] J. L. Halcombe, T. Livinghouse, *J. Org. Chem.* **1986**, *51*, 111–114.
- [31] Yamaguchi lactonization of **31** gave **32** in lower yield (**32**: 33 %, **33**: 6 %, dimer: 30 %): J. Inanaga, K. Hirata, H. Saeki, T. Katsuki, M. Yamaguchi, *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989–1993.
- [32] Bis-Boc protection of the amine was found to have a dramatic effect on the yield of the nine-membered ring cyclization.<sup>[19b]</sup>
- [33] Cope rearrangement of the nine-membered cyclic 1,5-diyne to the bisallene is considered to be the major decomposition pathway.<sup>[18]</sup>